Compare Summit Therapeutics Inc (SMMT) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wayfair Inc — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Wayfair Inc trades at $105.74 (market cap $14.40B). The key difference: Summit Therapeutics Inc and Wayfair Inc are close in size by market cap, and Wayfair Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Wayfair Inc for 8 Days on average.
| SMMT | W | |
|---|---|---|
Market Cap | $13.71B | $14.40B |
Volume | 6,173,057 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $119.05 |
52-Week Low | $12.43 | $57.40 |
Typical Hold Time | 16 Days | 8 Days |
Enterprise Value | $13.04B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Wayfair (W) trades at $105.74, up 1.22% today, with bullish technical signals from moving averages and a consensus analyst price target of $114.13. The company maintains strong revenue growth ($12.9B in 2026) but faces profitability challenges with negative net margins (-2.49%). Recent developments include the launch of the 'Wayfair Delivers' brand platform and upcoming Q3 2026 earnings on November 4, 2026.
Investment outlook remains cautiously optimistic given analyst support (54% buy ratings) and positive technical momentum, though persistent unprofitability and high debt-to-asset ratio (95% in 2025) present significant risks. The stock offers upside to price targets if margin improvements materialize, but requires monitoring of cash flow trends and competitive pressures in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
